No Data
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Cogent Biosciences Is Maintained at Buy by Citigroup
Express News | Cogent Biosciences Inc : Citigroup Raises Target Price to $15 From $13
Citi Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $15
Citi analyst David Lebowitz maintains $Cogent Biosciences(COGT.US)$ with a buy rating, and adjusts the target price from $13 to $15.According to TipRanks data, the analyst has a success rate of 53.7%
Analysts Conflicted on These Healthcare Names: American Well (AMWL), Cogent Biosciences (COGT) and NeoGenomics (NEO)
Companies Like Cogent Biosciences (NASDAQ:COGT) Are In A Position To Invest In Growth